SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
NEW YORK, Jan. 22, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased MannKind Corp. (Nasdaq:MNKD) securities between August 10, 2015 and January 5, 2016.
Click here to learn about the case: http://docs.wongesq.com/MNKD-Info-Request-Form-1078. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/MNKD-Info-Request-Form-1078.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
